# Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

> **NCT06457477** · NA · RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** NAs
- **DRUG:** Peg-IFNα-2b

## Key facts

- **NCT ID:** NCT06457477
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-15
- **Primary completion:** 2025-12-15
- **Final completion:** 2025-12-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06457477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06457477, "Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06457477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*